Lead Product(s) : Pimecrolimus
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment
Details : Pimecrolimus is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Blepharitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 06, 2024
Lead Product(s) : Pimecrolimus
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pimecrolimus
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pimecrolimus is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 29, 2017
Lead Product(s) : Pimecrolimus
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pimecrolimus
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : DPT Laboratories, Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pimecrolimus is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 11, 2017
Lead Product(s) : Pimecrolimus
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : DPT Laboratories, Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pimecrolimus
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis
Details : Pimecrolimus is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 12, 2016
Lead Product(s) : Pimecrolimus
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pimecrolimus
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pimecrolimus is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 06, 2016
Lead Product(s) : Pimecrolimus
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pimecrolimus
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)
Details : Pimecrolimus is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 03, 2015
Lead Product(s) : Pimecrolimus
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pimecrolimus
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pimecrolimus is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 04, 2014
Lead Product(s) : Pimecrolimus
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pimecrolimus
Therapeutic Area : Dermatology
Study Phase : Phase IV
Sponsor : Ferndale Laboratories, Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pimecrolimus is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 09, 2010
Lead Product(s) : Pimecrolimus
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Sponsor : Ferndale Laboratories, Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pimecrolimus
Therapeutic Area : Dermatology
Study Phase : Undisclosed
Sponsor : Deutsche Forschungsgemeinschaft, Bonn, Germany | Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Pimecrolimus and Epidermal Barrier Function
Details : Pimecrolimus is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 27, 2010
Lead Product(s) : Pimecrolimus
Therapeutic Area : Dermatology
Highest Development Status : Undisclosed
Sponsor : Deutsche Forschungsgemeinschaft, Bonn, Germany | Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
